{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:14:40Z","timestamp":1788315280273,"version":"build-2803163510"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Guangxi Science and Technology Innovation Platform Plan","award":["Guike LT2600640002"],"award-info":[{"award-number":["Guike LT2600640002"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260438"],"award-info":[{"award-number":["82260438"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012547","name":"Natural Science Foundation of Guangxi Zhuang Autonomous Region","doi-asserted-by":"publisher","award":["2023GXNSFDA026058"],"award-info":[{"award-number":["2023GXNSFDA026058"]}],"id":[{"id":"10.13039\/100012547","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05870-0","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:26:06Z","timestamp":1788312366000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mapping the global research landscape of risankizumab: a decade (2016\u20132025) of multi-database bibliometric analysis and emerging frontiers"],"prefix":"10.1007","author":[{"given":"Saiya","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongyuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"8018","key":"5870_CR1","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41586-024-07537-3","volume":"630","author":"A Ahmed","year":"2024","unstructured":"Ahmed A, Joseph AM, Zhou J et al (2024) CTLA-4 expressing ILC3s restrain interleukin-23 mediated inflammation. Nature 630(8018):976\u2013983. https:\/\/doi.org\/10.1038\/s41586-024-07537-3","journal-title":"Nature"},{"issue":"10","key":"5870_CR2","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1007\/s13555-024-01268-z","volume":"14","author":"AF Alexis","year":"2024","unstructured":"Alexis AF, Gooderham M, Kwatra SG et al (2024) A descriptive, post hoc analysis of efficacy and safety of risankizumab in diverse racial and ethnic patient populations with moderate-to-severe psoriasis. Dermatol Ther 14(10):2877\u20132887. https:\/\/doi.org\/10.1007\/s13555-024-01268-z","journal-title":"Dermatol Ther"},{"issue":"7","key":"5870_CR3","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1053\/j.gastro.2024.07.046","volume":"167","author":"AN Ananthakrishnan","year":"2024","unstructured":"Ananthakrishnan AN, Hassan Murad M, Scott FI et al (2024) Comparative efficacy of advanced therapies for management of moderate-to-severe ulcerative colitis: 2024 AGA evidence synthesis. Gastroenterology 167(7):1460\u20131482. https:\/\/doi.org\/10.1053\/j.gastro.2024.07.046","journal-title":"Gastroenterology"},{"issue":"14","key":"5870_CR4","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"GM Bartelds","year":"2011","unstructured":"Bartelds GM (2011) Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 305(14):1460. https:\/\/doi.org\/10.1001\/jama.2011.406","journal-title":"JAMA"},{"issue":"September","key":"5870_CR5","doi-asserted-by":"publisher","first-page":"770275","DOI":"10.3389\/fimmu.2021.770275","volume":"12","author":"E Bianchi","year":"2021","unstructured":"Bianchi E, Vecellio M, Rogge L (2021) Editorial: role of the IL-23\/IL-17 pathway in chronic immune-mediated inflammatory diseases: mechanisms and targeted therapies. Front Immunol 12(September):770275. https:\/\/doi.org\/10.3389\/fimmu.2021.770275","journal-title":"Front Immunol"},{"issue":"12","key":"5870_CR6","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s40265-020-01357-1","volume":"80","author":"HA Blair","year":"2020","unstructured":"Blair HA (2020) Risankizumab: a review in moderate to severe plaque psoriasis. Drugs 80(12):1235\u20131245. https:\/\/doi.org\/10.1007\/s40265-020-01357-1","journal-title":"Drugs"},{"key":"5870_CR7","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/s41467-025-67475-0","volume":"17","author":"A Blauvelt","year":"2025","unstructured":"Blauvelt A, Jiang R, Shi L et al (2025) A randomized phase 2 clinical trial to treat moderate-to-severe plaque psoriasis patients with high-induction dosing of risankizumab. Nat Commun 17:733. https:\/\/doi.org\/10.1038\/s41467-025-67475-0","journal-title":"Nat Commun"},{"issue":"14","key":"5870_CR8","doi-asserted-by":"publisher","first-page":"3394","DOI":"10.3390\/ijms20143394","volume":"20","author":"K Bunte","year":"2019","unstructured":"Bunte K, Beikler T (2019) Th17 cells and the IL-23\/IL-17 axis in the pathogenesis of periodontitis and immune-mediated inflammatory diseases. Int J Mol Sci 20(14):3394. https:\/\/doi.org\/10.3390\/ijms20143394","journal-title":"Int J Mol Sci"},{"issue":"7","key":"5870_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071933","volume":"15","author":"F Calapai","year":"2023","unstructured":"Calapai F, Ammendolia I, Cardia L et al (2023) Pharmacovigilance of risankizumab in the treatment of psoriasis and arthritic psoriasis: real-world data from EudraVigilance database. Pharmaceutics 15(7):1933. https:\/\/doi.org\/10.3390\/pharmaceutics15071933","journal-title":"Pharmaceutics"},{"issue":"10340","key":"5870_CR10","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","volume":"399","author":"G D\u2019Haens","year":"2022","unstructured":"D\u2019Haens G, Panaccione R, Baert F et al (2022) Risankizumab as induction therapy for Crohn\u2019s disease: results from the Phase 3 ADVANCE and MOTIVATE induction trials. The Lancet 399(10340):2015\u20132030. https:\/\/doi.org\/10.1016\/S0140-6736(22)00467-6","journal-title":"The Lancet"},{"key":"5870_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2024.103167","volume":"143","author":"H Furuya","year":"2024","unstructured":"Furuya H, Nguyen CT, Chan T et al (2024) IL-23 induces CLEC5A+ IL-17A+ neutrophils and elicit skin inflammation associated with psoriatic arthritis. J Autoimmun 143:103167. https:\/\/doi.org\/10.1016\/j.jaut.2024.103167","journal-title":"J Autoimmun"},{"issue":"10275","key":"5870_CR12","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","volume":"397","author":"K Ghoreschi","year":"2021","unstructured":"Ghoreschi K, Balato A, Enerb\u00e4ck C, Sabat R (2021) Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet 397(10275):754\u2013766. https:\/\/doi.org\/10.1016\/S0140-6736(21)00184-7","journal-title":"Lancet"},{"issue":"10148","key":"5870_CR13","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M et al (2018) Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 392(10148):650\u2013661. https:\/\/doi.org\/10.1016\/S0140-6736(18)31713-6","journal-title":"Lancet"},{"issue":"3","key":"5870_CR14","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1111\/bjd.20818","volume":"186","author":"KB Gordon","year":"2022","unstructured":"Gordon KB, Lebwohl M, Papp KA et al (2022) Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 186(3):466\u2013475. https:\/\/doi.org\/10.1111\/bjd.20818","journal-title":"Br J Dermatol"},{"issue":"Suppl 2","key":"5870_CR15","doi-asserted-by":"publisher","first-page":"ii73","DOI":"10.1093\/ecco-jcc\/jjab190","volume":"16","author":"ZS Gottlieb","year":"2021","unstructured":"Gottlieb ZS, Sands BE (2021) Personalised medicine with IL-23 blockers: myth or reality? J Crohn\u2019s & Colitis 16(Suppl 2):ii73-94. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab190","journal-title":"J Crohn\u2019s & Colitis"},{"issue":"5","key":"5870_CR16","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1093\/cvr\/cvaa257","volume":"117","author":"A Higaki","year":"2021","unstructured":"Higaki A, Mahmoud AUM, Paradis P, Schiffrin EL (2021) Role of interleukin-23\/Interleukin-17 axis in T-cell-mediated actions in hypertension. Cardiovasc Res 117(5):1274\u20131283. https:\/\/doi.org\/10.1093\/cvr\/cvaa257","journal-title":"Cardiovasc Res"},{"issue":"4","key":"5870_CR17","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s10928-018-9581-1","volume":"45","author":"C Hu","year":"2018","unstructured":"Hu C, Yao Z, Chen Y et al (2018) A comprehensive evaluation of exposure\u2013response relationships in clinical trials: application to support guselkumab dose selection for patients with psoriasis. J Pharmacokinet Pharmacodyn 45(4):523\u2013535. https:\/\/doi.org\/10.1007\/s10928-018-9581-1","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"15","key":"5870_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e35446","volume":"10","author":"S Huang","year":"2024","unstructured":"Huang S, Duan X, Bai Y (2024) Research trends and hotspots in biologics for plaque psoriasis: a bibliometric study from 2004 to 2023. Heliyon 10(15):e35446. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e35446","journal-title":"Heliyon"},{"issue":"6","key":"5870_CR19","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1159\/000542217","volume":"186","author":"YD Jeong","year":"2024","unstructured":"Jeong YD, Jo H, Cho H et al (2024) Biologics use for psoriasis during pregnancy and its related adverse outcomes in pregnant women and newborns: findings from WHO pharmacovigilance study. Int Arch Allergy Immunol 186(6):579\u2013593. https:\/\/doi.org\/10.1159\/000542217","journal-title":"Int Arch Allergy Immunol"},{"issue":"8","key":"5870_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084301","volume":"23","author":"RG Kamperman","year":"2022","unstructured":"Kamperman RG, van der Kooi AJ, de Visser M, Aronica E, Raaphorst J (2022) Pathophysiological mechanisms and treatment of dermatomyositis and immune mediated necrotizing myopathies: a focused review. Int J Mol Sci 23(8):4301. https:\/\/doi.org\/10.3390\/ijms23084301","journal-title":"Int J Mol Sci"},{"issue":"24","key":"5870_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12247653","volume":"12","author":"D-H Kang","year":"2023","unstructured":"Kang D-H, Lew B-L, Kwon S-H (2023) Incidence of new-onset inflammatory bowel disease, oral and gastrointestinal candidiasis, herpes zoster, pulmonary tuberculosis, and major cardiovascular events in patients with moderate-to-severe psoriasis exposed to biologics. J Clin Med 12(24):7653. https:\/\/doi.org\/10.3390\/jcm12247653","journal-title":"J Clin Med"},{"issue":"11","key":"5870_CR22","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1001\/jama.2024.8819","volume":"332","author":"GG Kaplan","year":"2024","unstructured":"Kaplan GG (2024) Monoclonal antibody risankizumab for ulcerative colitis. JAMA 332(11):877. https:\/\/doi.org\/10.1001\/jama.2024.8819","journal-title":"JAMA"},{"issue":"2","key":"5870_CR23","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1002\/cpt.1594","volume":"107","author":"A Khatri","year":"2020","unstructured":"Khatri A, Suleiman AA, Polepally AR, Othman AA (2020) Exposure\u2013response relationships for efficacy and safety of risankizumab in phase II and III trials in psoriasis patients. Clin Pharmacol Ther 107(2):378\u2013387. https:\/\/doi.org\/10.1002\/cpt.1594","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"5870_CR24","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1146\/annurev-med-042915-103905","volume":"68","author":"J Kim","year":"2017","unstructured":"Kim J, Krueger JG (2017) Highly effective new treatments for psoriasis target the IL-23\/type 17 T cell autoimmune axis. Annu Rev Med 68(1):255\u2013269. https:\/\/doi.org\/10.1146\/annurev-med-042915-103905","journal-title":"Annu Rev Med"},{"issue":"6","key":"5870_CR25","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1016\/j.jaci.2025.02.008","volume":"155","author":"J Kim","year":"2025","unstructured":"Kim J, Lee J, Lee J et al (2025) Psoriasis harbors multiple pathogenic type 17 T-cell subsets: selective modulation by risankizumab. J Allergy Clin Immunol 155(6):1898\u20131912. https:\/\/doi.org\/10.1016\/j.jaci.2025.02.008","journal-title":"J Allergy Clin Immunol"},{"key":"5870_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1331217","volume":"15","author":"JG Krueger","year":"2024","unstructured":"Krueger JG, Eyerich K, Kuchroo VK et al (2024) IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy. Front Immunol 15:1331217. https:\/\/doi.org\/10.3389\/fimmu.2024.1331217","journal-title":"Front Immunol"},{"issue":"12","key":"5870_CR27","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1016\/j.cgh.2024.12.007","volume":"23","author":"HH Lee","year":"2025","unstructured":"Lee HH, Solitano V, Singh S et al (2025) Differential efficacy of advanced therapies in inducing remission in ulcerative colitis based on prior exposure to TNF antagonists. Clin Gastroenterol Hepatol\u202f: Off Clin Pract J Am Gastroenterol Assoc 23(12):2102-2114.e5. https:\/\/doi.org\/10.1016\/j.cgh.2024.12.007","journal-title":"Clin Gastroenterol Hepatol : Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"March","key":"5870_CR28","doi-asserted-by":"publisher","first-page":"42081","DOI":"10.2340\/actadv.v105.42081","volume":"105","author":"J Li","year":"2025","unstructured":"Li J, Xiang X, Wang Z, Miao C, Chen Y, Zigang X (2025) Safety of interleukin inhibitors in psoriatic patients with latent tuberculosis infection without chemoprophylaxis: a systematic review. Acta Derm Venereol 105(March):42081. https:\/\/doi.org\/10.2340\/actadv.v105.42081","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"5870_CR29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.23736\/S2784-8671.24.07996-9","volume":"160","author":"F Lin","year":"2025","unstructured":"Lin F, Tsai T-F (2025) Efficacy and safety of risankizumab for the treatment of patients with plaque type psoriasis. Ital J Dermatol Venereol 160(2):155\u2013164. https:\/\/doi.org\/10.23736\/S2784-8671.24.07996-9","journal-title":"Ital J Dermatol Venereol"},{"issue":"November","key":"5870_CR30","doi-asserted-by":"publisher","first-page":"594735","DOI":"10.3389\/fimmu.2020.594735","volume":"11","author":"T Liu","year":"2020","unstructured":"Liu T, Li S, Ying S et al (2020) The IL-23\/IL-17 pathway in inflammatory skin diseases: from bench to bedside. Front Immunol 11(November):594735. https:\/\/doi.org\/10.3389\/fimmu.2020.594735","journal-title":"Front Immunol"},{"issue":"11","key":"5870_CR31","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1001\/jama.2024.12414","volume":"332","author":"E Louis","year":"2024","unstructured":"Louis E, Schreiber S, Panaccione R et al (2024) Risankizumab for ulcerative colitis: two randomized clinical trials. JAMA 332(11):881. https:\/\/doi.org\/10.1001\/jama.2024.12414","journal-title":"JAMA"},{"issue":"6","key":"5870_CR32","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1080\/09546634.2022.2081655","volume":"33","author":"M Megna","year":"2022","unstructured":"Megna M, Tommasino N, Potestio L et al (2022) Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat 33(6):2813\u20132820. https:\/\/doi.org\/10.1080\/09546634.2022.2081655","journal-title":"J Dermatolog Treat"},{"issue":"9","key":"5870_CR33","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.3390\/jcm12093233","volume":"12","author":"M Megna","year":"2023","unstructured":"Megna M, Ruggiero A, Battista T, Marano L, Cacciapuoti S, Potestio L (2023) Long-term efficacy and safety of risankizumab for moderate to severe psoriasis: a 2-year real-life retrospective study. J Clin Med 12(9):3233. https:\/\/doi.org\/10.3390\/jcm12093233","journal-title":"J Clin Med"},{"key":"5870_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.885672","volume":"13","author":"R Mosch","year":"2022","unstructured":"Mosch R, Guchelaar H-J (2022) Immunogenicity of monoclonal antibodies and the potential use of HLA haplotypes to predict vulnerable patients. Front Immunol 13:885672. https:\/\/doi.org\/10.3389\/fimmu.2022.885672","journal-title":"Front Immunol"},{"issue":"4","key":"5870_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40259-016-0181-6","volume":"30","author":"DR Mould","year":"2016","unstructured":"Mould DR, Meibohm B (2016) Drug development of therapeutic monoclonal antibodies. BioDrugs 30(4):275\u2013293. https:\/\/doi.org\/10.1007\/s40259-016-0181-6","journal-title":"BioDrugs"},{"issue":"Suppl 4","key":"5870_CR36","doi-asserted-by":"publisher","first-page":"iv4","DOI":"10.1093\/rheumatology\/keab266","volume":"60","author":"A Najm","year":"2021","unstructured":"Najm A, McInnes IB (2021) IL-23 orchestrating immune cell activation in arthritis. Rheumatology (Oxford) 60(Suppl 4):iv4-15. https:\/\/doi.org\/10.1093\/rheumatology\/keab266","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"5870_CR37","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202345","volume":"218","author":"S Nakamizo","year":"2021","unstructured":"Nakamizo S, Dutertre C-A, Khalilnezhad A et al (2021) Single-cell analysis of human skin identifies CD14+ type 3 dendritic cells co-producing IL1B and IL23A in psoriasis. J Exp Med 218(9):e20202345. https:\/\/doi.org\/10.1084\/jem.20202345","journal-title":"J Exp Med"},{"key":"5870_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1191782","volume":"14","author":"V Navarro-Comp\u00e1n","year":"2023","unstructured":"Navarro-Comp\u00e1n V, Puig L, Vidal S et al (2023) The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases. Front Immunol 14:1191782. https:\/\/doi.org\/10.3389\/fimmu.2023.1191782","journal-title":"Front Immunol"},{"issue":"10","key":"5870_CR39","doi-asserted-by":"publisher","DOI":"10.7326\/J22-0080","volume":"175","author":"D Oliver","year":"2022","unstructured":"Oliver D, Talley NJ (2022) In active Crohn disease, risankizumab increased clinical remission and endoscopic response at 12 wk. Ann Intern Med 175(10):JC114. https:\/\/doi.org\/10.7326\/J22-0080","journal-title":"Ann Intern Med"},{"issue":"11","key":"5870_CR40","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/j.cgh.2024.12.023","volume":"23","author":"R Panaccione","year":"2025","unstructured":"Panaccione R, Ferrante M, Dotan I et al (2025) Extended risankizumab treatment in patients with Crohn\u2019s disease who did not achieve clinical response to induction treatment. Clin Gastroenterol Hepatol 23(11):2012-2022.e6. https:\/\/doi.org\/10.1016\/j.cgh.2024.12.023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"5870_CR41","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s40262-019-00842-5","volume":"59","author":"Y Pang","year":"2020","unstructured":"Pang Y, Khatri A, Suleiman AA, Othman AA (2020) Clinical pharmacokinetics and pharmacodynamics of risankizumab in psoriasis patients. Clin Pharmacokinet 59(3):311\u2013326. https:\/\/doi.org\/10.1007\/s40262-019-00842-5","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"5870_CR42","doi-asserted-by":"publisher","first-page":"e13706","DOI":"10.1111\/cts.13706","volume":"17","author":"Y Pang","year":"2024","unstructured":"Pang Y, D\u2019Cunha R, Winzenborg I, Veldman G, Pivorunas V, Wallace K (2024) Risankizumab: mechanism of action, clinical and translational science. Clin Transl Sci 17(1):e13706. https:\/\/doi.org\/10.1111\/cts.13706","journal-title":"Clin Transl Sci"},{"issue":"6","key":"5870_CR43","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/bjd.20595","volume":"185","author":"KA Papp","year":"2021","unstructured":"Papp KA, Lebwohl MG, Puig L et al (2021) Long\u2010term efficacy and safety of risankizumab for the treatment of moderate\u2010to\u2010severe plaque psoriasis: interim analysis of the LIMMitless open\u2010label extension trial beyond 3 years of follow\u2010up. Br J Dermatol 185(6):1135\u20131145. https:\/\/doi.org\/10.1111\/bjd.20595","journal-title":"Br J Dermatol"},{"issue":"6","key":"5870_CR44","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jaad.2023.07.1024","volume":"89","author":"KA Papp","year":"2023","unstructured":"Papp KA, Blauvelt A, Puig L et al (2023) Long-term safety and efficacy of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial up to 5 years of follow-up. J Am Acad Dermatol 89(6):1149\u20131158. https:\/\/doi.org\/10.1016\/j.jaad.2023.07.1024","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"5870_CR45","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1038\/s12276-025-01535-9","volume":"57","author":"E Park","year":"2025","unstructured":"Park E, Ciofani M (2025) Th17 cell pathogenicity in autoimmune disease. Exp Mol Med 57(9):1913\u20131927. https:\/\/doi.org\/10.1038\/s12276-025-01535-9","journal-title":"Exp Mol Med"},{"issue":"4","key":"5870_CR46","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s40262-023-01221-x","volume":"62","author":"AV Ponce-Bobadilla","year":"2023","unstructured":"Ponce-Bobadilla AV, Stodtmann S, Chen M-J et al (2023) Assessing the impact of immunogenicity and improving prediction of trough concentrations: population pharmacokinetic modeling of adalimumab in patients with Crohn\u2019s disease and ulcerative colitis. Clin Pharmacokinet 62(4):623\u2013634. https:\/\/doi.org\/10.1007\/s40262-023-01221-x","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"5870_CR47","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1016\/j.cgh.2024.03.039","volume":"22","author":"X Roblin","year":"2024","unstructured":"Roblin X, Moschetti E, Barrau M, Cheifetz AS, Papamichael K, Paul S (2024) Risankizumab concentration but not IL-22 levels are associated with clinical and biochemical remission in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol 22(11):2340-2343.e2. https:\/\/doi.org\/10.1016\/j.cgh.2024.03.039","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"5870_CR48","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B (2017) Pharmacokinetics of monoclonal antibodies. CPT Pharmacomet Syst Pharmacol 6(9):576\u2013588. https:\/\/doi.org\/10.1002\/psp4.12224","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"2","key":"5870_CR49","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.abd.2024.05.005","volume":"100","author":"LB Sel\u00e7uk","year":"2025","unstructured":"Sel\u00e7uk LB, Ermi\u015f Akku\u015f H, Ak\u015fan B, Aksu Ar\u0131ca D (2025) Risankizumab and guselkumab for psoriasis: a 1-year real-world practice indirect comparison. An Bras Dermatol 100(2):293\u2013299. https:\/\/doi.org\/10.1016\/j.abd.2024.05.005","journal-title":"An Bras Dermatol"},{"issue":"2","key":"5870_CR50","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.cgh.2024.07.033","volume":"23","author":"M Shehab","year":"2025","unstructured":"Shehab M, Alrashed F, Alsayegh A et al (2025) Comparative efficacy of biologics and small molecule in ulcerative colitis: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol 23(2):250\u2013262. https:\/\/doi.org\/10.1016\/j.cgh.2024.07.033","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5870_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1169735","volume":"14","author":"Y Shu","year":"2023","unstructured":"Shu Y, Chen J, Ding Y, Zhang Q (2023) Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system. Front Immunol 14:1169735. https:\/\/doi.org\/10.3389\/fimmu.2023.1169735","journal-title":"Front Immunol"},{"issue":"7","key":"5870_CR52","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1053\/j.gastro.2024.10.001","volume":"167","author":"S Singh","year":"2024","unstructured":"Singh S, Loftus EV, Limketkai BN et al (2024) Aga living guidelines: pharmacological management of moderate-to-severe ulcerative colitis. Gastroenterology 167(7):1307\u20131343. https:\/\/doi.org\/10.1053\/j.gastro.2024.10.001","journal-title":"Gastroenterology"},{"issue":"2","key":"5870_CR53","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41584-020-00540-8","volume":"17","author":"V Strand","year":"2021","unstructured":"Strand V, Goncalves J, Isaacs JD (2021) Immunogenicity of biologic agents in rheumatology. Nat Rev Rheumatol 17(2):81\u201397. https:\/\/doi.org\/10.1038\/s41584-020-00540-8","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"5870_CR54","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1111\/jdv.19748","volume":"38","author":"B Strober","year":"2024","unstructured":"Strober B, Bachelez H, Crowley J et al (2024) Efficacy of long-term risankizumab treatment for moderate-to-severe plaque psoriasis: subgroup analyses by baseline characteristics and psoriatic disease manifestations through 256 weeks ( LIMMITLESS Trial). J Eur Acad Dermatol Venereol 38(5):864\u2013872. https:\/\/doi.org\/10.1111\/jdv.19748","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"5870_CR55","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1080\/14712598.2024.2401148","volume":"24","author":"Q-Y Su","year":"2024","unstructured":"Su Q-Y, Gao H-Y, Duan Y-R et al (2024) The immunologic role of IL-23 in psoriatic arthritis: a potential therapeutic target. Expert Opin Biol Ther 24(10):1119\u20131132. https:\/\/doi.org\/10.1080\/14712598.2024.2401148","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"5870_CR56","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s40262-018-0704-z","volume":"58","author":"AA Suleiman","year":"2019","unstructured":"Suleiman AA, Khatri A, Minocha M, Othman AA (2019a) Population pharmacokinetics of the interleukin-23 inhibitor risankizumab in subjects with psoriasis and Crohn\u2019s disease: analyses of phase I and II trials. Clin Pharmacokinet 58(3):375\u2013387. https:\/\/doi.org\/10.1007\/s40262-018-0704-z","journal-title":"Clin Pharmacokinet"},{"issue":"10","key":"5870_CR57","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s40262-019-00759-z","volume":"58","author":"AA Suleiman","year":"2019","unstructured":"Suleiman AA, Minocha M, Khatri A, Pang Y, Othman AA (2019b) Population pharmacokinetics of risankizumab in healthy volunteers and subjects with moderate to severe plaque psoriasis: integrated analyses of phase I\u2013III clinical trials. Clin Pharmacokinet 58(10):1309\u20131321. https:\/\/doi.org\/10.1007\/s40262-019-00759-z","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"5870_CR58","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40262-019-00829-2","volume":"59","author":"AA Suleiman","year":"2020","unstructured":"Suleiman AA, Khatri A, Oberoi RK, Othman AA (2020) Exposure\u2013response relationships for the efficacy and safety of risankizumab in Japanese subjects with psoriasis. Clin Pharmacokinet 59(5):575\u2013589. https:\/\/doi.org\/10.1007\/s40262-019-00829-2","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"5870_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-62874-9","volume":"16","author":"Y Sun","year":"2025","unstructured":"Sun Y, Lou F, Cai X et al (2025) CCR7+ dendritic cells expressing both IL-23A and IL-12B potentially contribute to psoriasis relapse. Nat Commun 16(1):7581. https:\/\/doi.org\/10.1038\/s41467-025-62874-9","journal-title":"Nat Commun"},{"issue":"10","key":"5870_CR60","doi-asserted-by":"publisher","first-page":"e2442204","DOI":"10.1001\/jamanetworkopen.2024.42204","volume":"7","author":"DA Taira","year":"2024","unstructured":"Taira DA, Ranken MS, Seto BK et al (2024) Representation of Native Hawaiian and Pacific Islander individuals in clinical trials. JAMA Netw Open 7(10):e2442204. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.42204","journal-title":"JAMA Netw Open"},{"issue":"7","key":"5870_CR61","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41575-023-00768-1","volume":"20","author":"B Verstockt","year":"2023","unstructured":"Verstockt B, Salas A, Sands BE et al (2023) IL-12 and IL-23 pathway inhibition in inflammatory bowel disease. Nat Rev Gastroenterol Hepatol 20(7):433\u2013446. https:\/\/doi.org\/10.1038\/s41575-023-00768-1","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"5870_CR62","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1016\/j.jaci.2018.11.042","volume":"143","author":"S Visvanathan","year":"2019","unstructured":"Visvanathan S, Baum P, Vinisko R et al (2019) Psoriatic skin molecular and histopathologic profiles after treatment with risankizumab versus ustekinumab. J Allergy Clin Immunol 143(6):2158\u20132169. https:\/\/doi.org\/10.1016\/j.jaci.2018.11.042","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"5870_CR63","doi-asserted-by":"publisher","first-page":"100222","DOI":"10.1016\/j.jacig.2024.100222","volume":"3","author":"Y Yao","year":"2024","unstructured":"Yao Y, Liu Z, Ji J, Jiao Q (2024) Mapping the intellectual structure of the research of omalizumab in chronic spontaneous urticaria: a bibliometric analysis. J Allergy Clin Immunol: Global 3(2):100222. https:\/\/doi.org\/10.1016\/j.jacig.2024.100222","journal-title":"J Allergy Clin Immunol: Global"},{"key":"5870_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/2802892","volume":"2022","author":"Q Yu","year":"2022","unstructured":"Yu Q, Ge X, Jing M et al (2022) A systematic review with meta-analysis of comparative efficacy and safety of risankizumab and ustekinumab for psoriasis treatment. J Immunol Res 2022:1\u201311. https:\/\/doi.org\/10.1155\/2022\/2802892","journal-title":"J Immunol Res"},{"issue":"November","key":"5870_CR65","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1186\/s40001-025-03346-0","volume":"30","author":"Y Yuan","year":"2025","unstructured":"Yuan Y, Li L, Yang L et al (2025) Single-cell RNA sequencing and in vitro validation reveal risankizumab induces anti-inflammatory macrophage polarization in psoriasis. Eur J Med Res 30(November):1114. https:\/\/doi.org\/10.1186\/s40001-025-03346-0","journal-title":"Eur J Med Res"},{"issue":"1","key":"5870_CR66","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1964420","volume":"13","author":"L Zhou","year":"2021","unstructured":"Zhou L, Wang Y, Wan Q et al (2021) A non-clinical comparative study of IL-23 antibodies in psoriasis. Mabs 13(1):1964420. https:\/\/doi.org\/10.1080\/19420862.2021.1964420","journal-title":"Mabs"},{"issue":"2","key":"5870_CR67","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1177\/0091270008329556","volume":"49","author":"Y Zhu","year":"2009","unstructured":"Zhu Y, Hu C, Lu M et al (2009) Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL\u201012\/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 49(2):162\u2013175. https:\/\/doi.org\/10.1177\/0091270008329556","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"5870_CR68","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.cgh.2024.09.027","volume":"23","author":"A Zinger","year":"2025","unstructured":"Zinger A, Choi D, Choi N et al (2025) Long-term effectiveness and safety of risankizumab in patients with Crohn\u2019s disease. Clin Gastroenterol Hepatol 23(10):1817\u20131823. https:\/\/doi.org\/10.1016\/j.cgh.2024.09.027","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05870-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05870-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05870-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:26:08Z","timestamp":1788312368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05870-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":68,"alternative-id":["5870"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05870-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"19 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}